Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 2.51% is 137% above its 5-year average of -6.84%, near the high end of its 5-year range (-24.23%–7.80%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.63% above its 12-month average of 2.10%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 2.51%.
RETURN ON EQUITY (ROE)
2.51%
RETURN ON EQUITY (ROE) AVG TTM
2.10%
RETURN ON EQUITY (ROE) AVG 3Y
-8.89%
RETURN ON EQUITY (ROE) AVG 5Y
-6.84%
RETURN ON EQUITY (ROE) AVG 10Y
-3.07%
RETURN ON EQUITY (ROE) AVG 15Y
-1.42%
RETURN ON EQUITY (ROE) AVG 20Y
-1.03%
CURRENT VS TTM AVG
+19.63%
CURRENT VS 3Y AVG
+128.24%
CURRENT VS 5Y AVG
+136.68%
CURRENT VS 10Y AVG
+181.74%
CURRENT VS 15Y AVG
+276.91%
CURRENT VS 20Y AVG
+344.21%
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
+106.24%
vs the sector median at left
ImmuCell Corporation
Market Cap
$88.48M
Return on Equity (ROE)
2.51%
TTM Avg
2.10%
3Y Avg
-8.89%
5Y Avg
-6.84%
Market Cap
$86.90M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$90.54M
Return on Equity (ROE)
48.20%
TTM Avg
-54.60%
3Y Avg
-54.70%
5Y Avg
-44.17%
Market Cap
$90.66M
Return on Equity (ROE)
-105.20%
TTM Avg
-53.79%
3Y Avg
-41.98%
5Y Avg
-32.71%
Market Cap
$86.81M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$90.73M
Return on Equity (ROE)
-32.15%
TTM Avg
-60.32%
3Y Avg
-93.79%
5Y Avg
-79.41%
Market Cap
$85.13M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$85.01M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$84.78M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $88.48M | 2.51% | 2.10% | -8.89% | -6.84% |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 45.93% | 16.96% | -19.36% | -13.87% |
| Rallybio Corporation (RLYB)vs › | $90.54M | 48.20% | -54.60% | -54.70% | -44.17% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $90.66M | -105.20% | -53.79% | -41.98% | -32.71% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.81M | N/A | 1.45% | 25.22% | -14.52% |
| Equillium, Inc. (EQ)vs › | $90.73M | -32.15% | -60.32% | -93.79% | -79.41% |
| Humacyte, Inc. (HUMA)vs › | $85.13M | -309.44% | -515.53% | -464.77% | -329.14% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | -50.80% | -124.86% | -88.30% | -60.21% |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | -150.95% | -77.89% | -62.90% | -47.80% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $92.22M | -477.87% | -156.51% | -83.51% | -25.98% |
ROE
2.5%
ROA
1.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 2.51% |
| 2026-03-31 | -1.87% |
| 2025-12-31 | -3.84% |
| 2025-09-30 | 7.80% |
| 2025-06-30 | 5.90% |
| 2025-03-31 | -0.94% |
| 2024-12-31 | -7.84% |
| 2024-09-30 | -14.43% |
| 2024-06-30 | -17.26% |
| 2024-03-31 | -15.82% |
| 2023-12-31 | -23.11% |
| 2023-09-30 | -24.23% |
| 2023-06-30 | -22.41% |
| 2023-03-31 | -18.90% |
| 2022-12-31 | -8.21% |
| 2022-09-30 | -2.35% |
| 2022-06-30 | 0.16% |
| 2022-03-31 | 2.63% |
| 2021-12-31 | -0.24% |
| 2021-09-30 | 0.11% |
| 2021-06-30 | -1.35% |
| 2021-03-31 | -4.81% |
| 2020-12-31 | -3.62% |
| 2020-09-30 | -5.43% |
| 2020-06-30 | -6.01% |
| 2020-03-31 | -5.39% |
| 2019-12-31 | -4.47% |
| 2019-09-30 | -6.98% |
| 2019-06-30 | -6.02% |
| 2019-03-31 | -6.47% |
| 2018-12-31 | -10.68% |
| 2018-09-30 | -6.46% |
| 2018-06-30 | -6.81% |
| 2018-03-31 | -4.15% |
| 2017-12-31 | -0.71% |
| 2017-09-30 | 0.27% |
| 2017-06-30 | 2.13% |
| 2017-03-31 | 3.14% |
| 2016-12-31 | 2.58% |
| 2016-09-30 | 4.67% |
| 2016-06-30 | 6.64% |
| 2016-03-31 | 7.27% |
| 2015-12-31 | 11.43% |
| 2015-09-30 | 10.24% |
| 2015-06-30 | 7.21% |
| 2015-03-31 | 3.34% |
| 2014-12-31 | -1.81% |
| 2014-09-30 | -4.92% |
| 2014-06-30 | -4.41% |
| 2014-03-31 | -1.07% |
| 2013-12-31 | 1.25% |
| 2013-09-30 | 2.64% |
| 2013-06-30 | 1.38% |
| 2013-03-31 | 1.48% |
| 2012-12-31 | 0.97% |
| 2012-09-30 | 1.15% |
| 2012-06-30 | 0.45% |
| 2012-03-31 | -2.50% |
| 2011-12-31 | -4.54% |
| 2011-09-30 | -5.97% |
| 2011-06-30 | -6.70% |
| 2011-03-31 | -3.83% |
| 2010-12-31 | -4.14% |
| 2010-09-30 | -2.91% |
| 2010-06-30 | -0.98% |
| 2010-03-31 | -2.45% |
| 2009-12-31 | -2.25% |
| 2009-09-30 | -2.51% |
| 2009-06-30 | -5.10% |
| 2009-03-31 | -5.96% |
| 2008-12-31 | -4.86% |
| 2008-09-30 | -3.67% |
| 2008-06-30 | 2.67% |
| 2008-03-31 | 4.36% |
| 2007-12-31 | 6.58% |
| 2007-09-30 | 7.48% |
| 2007-06-30 | 5.83% |
| 2007-03-31 | 6.60% |
| 2006-12-31 | 6.93% |
| 2006-09-30 | 8.16% |
| 2006-06-30 | 7.62% |
| 2006-03-31 | 8.47% |
| 2005-12-31 | 8.27% |
| 2005-09-30 | 5.82% |
| 2005-06-30 | 4.50% |
| 2005-03-31 | 2.89% |
| 2004-12-31 | 1.86% |
| 2004-09-30 | -0.25% |
| 2004-06-30 | -0.69% |
| 2004-03-31 | -1.56% |
| 2003-12-31 | 5.58% |
| 2003-09-30 | 16.65% |
| 2003-06-30 | 17.47% |
